What is Rigel Pharmaceuticals's long-term debt?

Rigel Pharmaceuticals (RIGL) reported long-term debt of $45M in Q1 2026.

What does long-term debt mean?

Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.

Rigel Pharmaceuticals RIGL Long-Term Debt

Long-Term Debt at other companies

AmgenAMGN

$51.89B-3.9%

Nuvation BioNUVB

$47.33M—

Zevra Therapeutics, Inc.ZVRA

$0-100%

Eton Pharmaceuticals, Inc.ETON

$18.94M-36.9%

XER

Xeris Biopharma Holdings, Inc.XERS

$221.22M+1.6%

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$58.8M+10.3%

Gross profit$54.2M+10.8%

Operating income$11.9M-7.0%

Net income$8.7M-24.4%

EPS (diluted)$0.44-30.2%

Balance sheet

See full

Cash & equivalents$24.5M-46.6%

Total debt$68.4M+5,079%

Total equity$399.9M+2,054%

Total assets$504.6M+187%

Cash flow

See full

Operating cash flow$2.7M+405%

CapEx$73.0K—

Free cash flow-$22.0M—

Valuation

See full

Market cap$684.39M+102%

Enterprise value$728.29M+148%

P/E1.9×-7.2×

P/S2.3×+0.6×

Profitability

See full

Gross margin93.4%+3.7pp

Operating margin41.6%+19.9pp

Net margin121.5%+103pp

FCF margin-61.7%—

Returns & leverage

See full

Return on equity174.1%—

Debt / equity0.2×+0.1×

Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebt.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rigel Pharmaceuticals's long-term debt?: Rigel Pharmaceuticals (RIGL) reported long-term debt of $45M in Q1 2026.
What does long-term debt mean?: Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.